Effect of hookworm infection and anthelmintic treatment on naturally acquired antibody responses against the GMZ2 malaria vaccine candidate and constituent antigens

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Effect of hookworm infection and anthelmintic treatment on naturally acquired antibody responses against the GMZ2 malaria vaccine candidate and constituent antigens. / Amoani, Benjamin; Gyan, Ben; Sakyi, Samuel Asamoah; Abu, Emmanuel Kwasi; Nuvor, Samuel Victor; Barnes, Precious; Sarkodie-Addo, Tracy; Ahenkorah, Benjamin; Sewor, Christian; Dwomoh, Duah; Theisen, Michael; Cappello, Michael; Wilson, Michael D; Adu, Bright.

I: BMC Infectious Diseases, Bind 21, Nr. 1, 332, 08.04.2021.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Amoani, B, Gyan, B, Sakyi, SA, Abu, EK, Nuvor, SV, Barnes, P, Sarkodie-Addo, T, Ahenkorah, B, Sewor, C, Dwomoh, D, Theisen, M, Cappello, M, Wilson, MD & Adu, B 2021, 'Effect of hookworm infection and anthelmintic treatment on naturally acquired antibody responses against the GMZ2 malaria vaccine candidate and constituent antigens', BMC Infectious Diseases, bind 21, nr. 1, 332. https://doi.org/10.1186/s12879-021-06027-5

APA

Amoani, B., Gyan, B., Sakyi, S. A., Abu, E. K., Nuvor, S. V., Barnes, P., Sarkodie-Addo, T., Ahenkorah, B., Sewor, C., Dwomoh, D., Theisen, M., Cappello, M., Wilson, M. D., & Adu, B. (2021). Effect of hookworm infection and anthelmintic treatment on naturally acquired antibody responses against the GMZ2 malaria vaccine candidate and constituent antigens. BMC Infectious Diseases, 21(1), [332]. https://doi.org/10.1186/s12879-021-06027-5

Vancouver

Amoani B, Gyan B, Sakyi SA, Abu EK, Nuvor SV, Barnes P o.a. Effect of hookworm infection and anthelmintic treatment on naturally acquired antibody responses against the GMZ2 malaria vaccine candidate and constituent antigens. BMC Infectious Diseases. 2021 apr. 8;21(1). 332. https://doi.org/10.1186/s12879-021-06027-5

Author

Amoani, Benjamin ; Gyan, Ben ; Sakyi, Samuel Asamoah ; Abu, Emmanuel Kwasi ; Nuvor, Samuel Victor ; Barnes, Precious ; Sarkodie-Addo, Tracy ; Ahenkorah, Benjamin ; Sewor, Christian ; Dwomoh, Duah ; Theisen, Michael ; Cappello, Michael ; Wilson, Michael D ; Adu, Bright. / Effect of hookworm infection and anthelmintic treatment on naturally acquired antibody responses against the GMZ2 malaria vaccine candidate and constituent antigens. I: BMC Infectious Diseases. 2021 ; Bind 21, Nr. 1.

Bibtex

@article{26ea31d1944548b795b4269366497946,
title = "Effect of hookworm infection and anthelmintic treatment on naturally acquired antibody responses against the GMZ2 malaria vaccine candidate and constituent antigens",
abstract = "BACKGROUND: Malaria and helminths diseases are co-endemic in most parts of sub-Saharan Africa. Immune responses from each of these pathogens interact, and these interactions may have implications on vaccines. The GMZ2 malaria vaccine candidate is a fusion protein of Plasmodium falciparum merozoite surface protein 3 (MSP3) and glutamate rich protein (GLURP R0). GMZ2 has recently showed modest efficacy in a phase IIb multicenter trial. Here, we assessed the effect of hookworm (Necator americanus) infection and anthelmintic treatment on naturally acquired antibody responses against GMZ2 and constituent antigens.METHODS: This longitudinal cross-sectional study was conducted in the Kintampo North Municipality of Ghana. Blood and stool samples were taken from 158 individuals (4-88 years old) infected with either P. falciparum alone (n = 59) or both hookworm and P. falciparum (n = 63) and uninfected endemic controls (n = 36). Stool hookworm infection was detected by the Kato-Katz method and PCR. Malaria parasitaemia was detected by RDT, light microscopy and P. falciparum-specific 18S rRNA gene PCR. Serum samples were obtained prior to hookworm treatment with a single dose of albendazole (400 mg) and 3 weeks (21 days) after treatment. Levels of IgG1, IgG3 and IgM against GMZ2, MSP3 and GLURP R0 were measured by ELISA and compared among the groups, before and after treatment.RESULTS: Participants with P. falciparum and hookworm co-infection had significantly higher IgG3 levels to GMZ2 than those with only P. falciparum infection and negative control (p < 0.05) at baseline. Treatment with albendazole led to a significant reduction in IgG3 levels against both GMZ2 and GLURP R0. Similarly, IgM and IgG1 levels against MSP3 also decreased following deworming treatment.CONCLUSION: Individuals with co-infection had higher antibody responses to GMZ2 antigen. Treatment of hookworm/malaria co-infection resulted in a reduction in antibody responses against GMZ2 and constituent antigens after albendazole treatment. Thus, hookworm infection and treatment could have a potential implication on malaria vaccine efficacy.",
author = "Benjamin Amoani and Ben Gyan and Sakyi, {Samuel Asamoah} and Abu, {Emmanuel Kwasi} and Nuvor, {Samuel Victor} and Precious Barnes and Tracy Sarkodie-Addo and Benjamin Ahenkorah and Christian Sewor and Duah Dwomoh and Michael Theisen and Michael Cappello and Wilson, {Michael D} and Bright Adu",
year = "2021",
month = apr,
day = "8",
doi = "10.1186/s12879-021-06027-5",
language = "English",
volume = "21",
journal = "B M C Infectious Diseases",
issn = "1471-2334",
publisher = "BioMed Central Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - Effect of hookworm infection and anthelmintic treatment on naturally acquired antibody responses against the GMZ2 malaria vaccine candidate and constituent antigens

AU - Amoani, Benjamin

AU - Gyan, Ben

AU - Sakyi, Samuel Asamoah

AU - Abu, Emmanuel Kwasi

AU - Nuvor, Samuel Victor

AU - Barnes, Precious

AU - Sarkodie-Addo, Tracy

AU - Ahenkorah, Benjamin

AU - Sewor, Christian

AU - Dwomoh, Duah

AU - Theisen, Michael

AU - Cappello, Michael

AU - Wilson, Michael D

AU - Adu, Bright

PY - 2021/4/8

Y1 - 2021/4/8

N2 - BACKGROUND: Malaria and helminths diseases are co-endemic in most parts of sub-Saharan Africa. Immune responses from each of these pathogens interact, and these interactions may have implications on vaccines. The GMZ2 malaria vaccine candidate is a fusion protein of Plasmodium falciparum merozoite surface protein 3 (MSP3) and glutamate rich protein (GLURP R0). GMZ2 has recently showed modest efficacy in a phase IIb multicenter trial. Here, we assessed the effect of hookworm (Necator americanus) infection and anthelmintic treatment on naturally acquired antibody responses against GMZ2 and constituent antigens.METHODS: This longitudinal cross-sectional study was conducted in the Kintampo North Municipality of Ghana. Blood and stool samples were taken from 158 individuals (4-88 years old) infected with either P. falciparum alone (n = 59) or both hookworm and P. falciparum (n = 63) and uninfected endemic controls (n = 36). Stool hookworm infection was detected by the Kato-Katz method and PCR. Malaria parasitaemia was detected by RDT, light microscopy and P. falciparum-specific 18S rRNA gene PCR. Serum samples were obtained prior to hookworm treatment with a single dose of albendazole (400 mg) and 3 weeks (21 days) after treatment. Levels of IgG1, IgG3 and IgM against GMZ2, MSP3 and GLURP R0 were measured by ELISA and compared among the groups, before and after treatment.RESULTS: Participants with P. falciparum and hookworm co-infection had significantly higher IgG3 levels to GMZ2 than those with only P. falciparum infection and negative control (p < 0.05) at baseline. Treatment with albendazole led to a significant reduction in IgG3 levels against both GMZ2 and GLURP R0. Similarly, IgM and IgG1 levels against MSP3 also decreased following deworming treatment.CONCLUSION: Individuals with co-infection had higher antibody responses to GMZ2 antigen. Treatment of hookworm/malaria co-infection resulted in a reduction in antibody responses against GMZ2 and constituent antigens after albendazole treatment. Thus, hookworm infection and treatment could have a potential implication on malaria vaccine efficacy.

AB - BACKGROUND: Malaria and helminths diseases are co-endemic in most parts of sub-Saharan Africa. Immune responses from each of these pathogens interact, and these interactions may have implications on vaccines. The GMZ2 malaria vaccine candidate is a fusion protein of Plasmodium falciparum merozoite surface protein 3 (MSP3) and glutamate rich protein (GLURP R0). GMZ2 has recently showed modest efficacy in a phase IIb multicenter trial. Here, we assessed the effect of hookworm (Necator americanus) infection and anthelmintic treatment on naturally acquired antibody responses against GMZ2 and constituent antigens.METHODS: This longitudinal cross-sectional study was conducted in the Kintampo North Municipality of Ghana. Blood and stool samples were taken from 158 individuals (4-88 years old) infected with either P. falciparum alone (n = 59) or both hookworm and P. falciparum (n = 63) and uninfected endemic controls (n = 36). Stool hookworm infection was detected by the Kato-Katz method and PCR. Malaria parasitaemia was detected by RDT, light microscopy and P. falciparum-specific 18S rRNA gene PCR. Serum samples were obtained prior to hookworm treatment with a single dose of albendazole (400 mg) and 3 weeks (21 days) after treatment. Levels of IgG1, IgG3 and IgM against GMZ2, MSP3 and GLURP R0 were measured by ELISA and compared among the groups, before and after treatment.RESULTS: Participants with P. falciparum and hookworm co-infection had significantly higher IgG3 levels to GMZ2 than those with only P. falciparum infection and negative control (p < 0.05) at baseline. Treatment with albendazole led to a significant reduction in IgG3 levels against both GMZ2 and GLURP R0. Similarly, IgM and IgG1 levels against MSP3 also decreased following deworming treatment.CONCLUSION: Individuals with co-infection had higher antibody responses to GMZ2 antigen. Treatment of hookworm/malaria co-infection resulted in a reduction in antibody responses against GMZ2 and constituent antigens after albendazole treatment. Thus, hookworm infection and treatment could have a potential implication on malaria vaccine efficacy.

U2 - 10.1186/s12879-021-06027-5

DO - 10.1186/s12879-021-06027-5

M3 - Journal article

C2 - 33832450

VL - 21

JO - B M C Infectious Diseases

JF - B M C Infectious Diseases

SN - 1471-2334

IS - 1

M1 - 332

ER -

ID: 259774519